Imperial College ECMC‘s main objectives are to develop novel imaging, biomarker and therapeutic approaches that will aid cancer diagnosis and deliver personalised treatment. One area we focus on is understanding and overcoming drug resistance in breast and ovarian cancers which has led to novel treatment strategies and evaluation of a range of biomarkers that help support therapeutic decisions.
Our ECMC centre has close alignment with the CRUK Imperial Centre, the Imperial NIHR Biomedical Research Centre and the Imperial College Academic Health Science Centre.
At Imperial, our cancer research is harnessed with forefront expertise in Physics, Chemistry and Engineering. This is exemplified by synthesis of series of novel PET Imaging probes that have been taken from laboratory to bedside and are now being used for cancer diagnosis and response assessment.
More recently, the Intelligent Knife (iKnife) device has been developed which during surgery, identifies tumour cells based on their biological characteristics and therefore enables surgeons to more efficiently remove traces of tumours.
Imperial College ECMC’s objectives is to establish the Imperial Cancer Biomarker Resource Centre (ICBRC) that will provide infrastructure support
To perform quality assured sample collection involving early phase trials and clinical studies
Evaluate and validate biomarkers using range of technology platforms including genomic, epigenomic, proteomic and metabolomics
Improved visualisation and characterisation of tumours through Imaging technologies
Provide bioinformatic and biostatistical analysis
Organisations affiliated with Imperial College ECMC:
Contact the Centre Manager: